explore -WSS

explore

author：Wikipedia 2025-09-06 04:12:52 - browse：37147

The Federal Trade Commission office glows softly inside, contrasting with the darkness outside — coverage from STAT — Adobe

Over the past two decades, hundreds of hospital mergers have escaped federal antitrust scrutiny and led to both higher prices and less competition, a new study shows.

But the study’s authors, and other researchers, believe the Federal Trade Commission’s hands often are tied. The agency simply doesn’t have enough money or people to crack down on all anticompetitive hospital deals, and some state laws shield hospital mergers from federal review completely.

“The resources available are just not commensurate with what the agency needs,” said Zack Cooper, an associate professor of health policy and economics at Yale University and one of the co-authors of the study. “This isn’t a story of the FTC not knowing what to do. I actually think they really know, very clearly, what to do. It’s a lack of resources, person power, and potentially willingness to do it.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Second House panel advances two

WSS

Cigna, Humana reportedly in talks to merge

Mayo Clinic plans $5B tech

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Flagship Pioneering launches a new biotech in two countries

With clinical trial data readouts, here's how to spot spin

Fetal surgery at risk from Dobbs and new abortion restrictions

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

U.K. Biobank has 500,000 peoples' genome sequences available

Virginia high school admissions case could be legal follow

Organ aging and disease risk measured by new blood test

How one medical school became remarkably diverse

Cytokinetics CEO stresses company can launch heart drug on its own

Wildfire smoke exposes gaps in outdoor worker protections

FDA investigates CAR

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Case highlights the risks of experimental stem cell therapy

focus

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Diagnostic tests are hitting their mathematical limits

As biotech industry slumps, bioscience job market is upside down

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Solving academic medical centers' existential crisis

explore

focus

hotspot

Wikipedia